Publications by authors named "Lilly Mark"

Claim this Profile
T
The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species.
Jessica Basso, Kuan-Ju Chen, Yuchen Zhou, Lilly Mark, Daniel LaSala

Front Pharmacol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural and Antibacterial Characterization of a New Benzamide FtsZ Inhibitor with Superior Bactericidal Activity and In Vivo Efficacy Against Multidrug-Resistant .
Eric Bryan, Edgar Ferrer-González, Hye Yeon Sagong, Junso Fujita, Lilly Mark

ACS Chem Biol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction for Plaunt et al., "Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections".
Adam J Plaunt, Sasha J Rose, Jeong Yeon Kang, Kuan-Ju Chen, Daniel LaSala, Lilly Mark

Antimicrob Agents Chemother· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination with a FtsZ inhibitor potentiates the in vivo efficacy of oxacillin against methicillin-resistant .
Malvika Kaul, Edgar Ferrer-González, Lilly Mark, Ajit K Parhi, Edmond J LaVoie

Med Chem Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections.
Adam J Plaunt, Sasha J Rose, Jeong Yeon Kang, Kuan-Ju Chen, Daniel LaSala, Lilly Mark

Antimicrob Agents Chemother· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining the FtsZ-Targeting Prodrug TXA709 and the Cephalosporin Cefdinir Confers Synergy and Reduces the Frequency of Resistance in Methicillin-Resistant Staphylococcus aureus.
Malvika Kaul, Lilly Mark, Ajit K Parhi, Edmond J LaVoie, Daniel S Pilch

Antimicrob Agents Chemother· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus.
Malvika Kaul, Lilly Mark, Yongzheng Zhang, Ajit K Parhi, Yi Lisa Lyu

Antimicrob Agents Chemother· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An FtsZ-targeting prodrug with oral antistaphylococcal efficacy in vivo.
Malvika Kaul, Lilly Mark, Yongzheng Zhang, Ajit K Parhi, Edmond J Lavoie

Antimicrob Agents Chemother· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and in vivo antistaphylococcal efficacy of TXY541, a 1-methylpiperidine-4-carboxamide prodrug of PC190723.
Malvika Kaul, Lilly Mark, Yongzheng Zhang, Ajit K Parhi, Edmond J LaVoie

Biochem Pharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152).
David J O'Neill, Adedayo Adedoyin, Jenifer A Bray, Darlene C Deecher, Andrew Fensome, Lilly Mark

J Med Chem· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system.
Pranab K Chanda, Ying Gao, Lilly Mark, Joan Btesh, Brian W Strassle

Mol Pharmacol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain is a salient "stressor" that is mediated by corticotropin-releasing factor-1 receptors.
Michele Hummel, Terri Cummons, Peimin Lu, Lilly Mark, James E Harrison

Neuropharmacology· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice.
Ying Gao, Dmitry V Vasilyev, Maria Beatriz Goncalves, Fiona V Howell, Carl Hobbs, Lilly Mark

J Neurosci· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.
Puwen Zhang, Eugene A Terefenko, Jenifer Bray, Darlene Deecher, Andrew Fensome, Lilly Mark

J Med Chem· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A personal reflection: critical care family communication.
Mark Lilly

Dimens Crit Care Nurs· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A personal reflection: family survival in the pediatric intensive care unit.
Mark Lilly

Dimens Crit Care Nurs· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: a potent, broad-spectrum state-dependent sodium channel blocker for treating pain states.
Victor I Ilyin, James D Pomonis, Garth T Whiteside, James E Harrison, Michelle S Pearson, Lilly Mark

J Pharmacol Exp Ther· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Garth T Whiteside, Susan L Gottshall, Jamie M Boulet, Suzanne M Chaffer, James E Harrison, Lilly Mark

Eur J Pharmacol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Kenneth J Valenzano, Laykea Tafesse, Gary Lee, James E Harrison, Jamie M Boulet, Lilly Mark

Neuropharmacology· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.
Garth T Whiteside, James E Harrison, Michelle S Pearson, Zhengming Chen, Marian E Fundytus, Lilly Mark

J Pharmacol Exp Ther· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterisation of a rat model of incisional pain.
Garth T Whiteside, James Harrison, Jamie Boulet, Lilly Mark, Michelle Pearson

Br J Pharmacol· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain.
James D Pomonis, James E Harrison, Lilly Mark, David R Bristol, Kenneth J Valenzano

J Pharmacol Exp Ther· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis